Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)

Measles Virus (MeV) Service

With increasing evidence of safety and efficacy in clinical trials, oncolytic viruses offer a ray of hope in fighting against cancers.


Our promise to you:
Guaranteed product quality, expert customer support.


Measles Virus (MeV) Service

With increasing evidence of safety and efficacy in clinical trials, oncolytic viruses offer a ray of hope in fighting against cancers. Live attenuated measles virus (MeV) can be developed for oncolytic use. Creative Biogene has developed Measles Virus (MeV) Platform with the goal of promoting the research progress in cancer treatment by means of oncolytic measles viruses.

MeV Introduction

Measles Virus (MeV) is an enveloped, single-stranded, negative-sense RNA virus in the genus of Morbillivirus of the family Paramyxoviridae. The MeV genome is comprised of approximately 16,000 nucleotides which encodes eight viral proteins including nucleoprotein (N), phosphoprotein (P), large protein (L), matrix protein (M), envelope glycoproteins hemagglutinin (H) and fusion (F) proteins.

Figure 1. Measles Virus (MeV)

Several types of viruses have been engineered for use as oncolytic vectors. Many of them have entered clinical trials and are showing inspiring data profiles, whether in safety or in efficacy. MeV is one such potential candidate due to its latent oncotropic and oncolytic features in nature. Genetic modifications allow MeVs to possess improved tumor selectivity, tumor targeting, tumor killing, and immune system modulation. So far, a list of genetically modified MeVs have been reported in using against a wide range of cancers, for example, MV-CEA, MV-NIS, MV-GMCSF, MV-MMP, MV-PNP, MV-CD133, MV-CD20, MV-CD38 etc., and many of them can destroy more than two types of cancer cells. Apparently, oncolytic MeVs have become important contenders in the field of cancer treatment.

MeV Design & Production

Genetic modifications on MeVs mainly include introducing 1) detectable markers to monitor viral infection, 2) transgenes to enhance oncolytic abilities and immune-modulatory activities, 3) mutations to retarget specific receptors overexpressed on tumor cells. Performing fast and successful genetic modifications on MeV is an important agent in the way of arming it to be a powerful cancer killer. Creative Biogene owns world-class facilities, advanced molecular biotechnologies, and experienced staffs with in-depth knowledge of MeV. Moreover, we have successfully tailor-constructed several modified MeVs for customers. Welcome to contact us at or 1-631-626-9181, if you need help in creating your own modified MeVs.

Figure 2. Genetic modifications of MeV


  • Gene delivery
  • Study and develop MeV-based oncolytic viruses

Our Service Includes

Figure 3. Service workflow


  1. Bellini WJ, Rota JS, Rota PA. Virology of measles virus. J Infect Dis. 1994 Nov;170 Suppl 1:S15-23.
  2. Hutzen B, Raffel C, Studebaker AW. Advances in the design and development of oncolytic measles viruses. Oncolytic Virother. 2015 Aug 27;4:109-18.
  3. Aref S, Bailey K, Fielding A. Measles to the Rescue: A Review of Oncolytic Measles Virus. Viruses. 2016 Oct 22;8(10). pii: E294.

Quick Inquiry

   Please input "biogene" as verification code.